Morphosys AG Subsidiary Constellation Pharmaceuticals Enters Into Global Licensing Agreement With Novartis

MorphoSys AG MOR:

• FULLY OWNED SUBSIDIARY CONSTELLATION PHARMACEUTICALS, INC. HAS ENTERED INTO A GLOBAL LICENSING AGREEMENT WITH NOVARTIS

• AGREEMENT WITH NOVARTIS INCLUDES RESEARCH, DEVELOP AND COMMERCIALIZE ITS PRE-CLINICAL INHIBITORS OF A NOVEL CANCER TARGET

• MORPHOSYS RECEIVES UPFRONT PAYMENT OF $23 MILLION, POTENTIAL MILESTONE PAYMENTS, PLUS MID-SINGLE- TO LOW-DOUBLE-DIGIT ROYALTIES ON NET SALES